Copyright
©The Author(s) 2024.
World J Methodol. Sep 20, 2024; 14(3): 92983
Published online Sep 20, 2024. doi: 10.5662/wjm.v14.i3.92983
Published online Sep 20, 2024. doi: 10.5662/wjm.v14.i3.92983
Ref. | Outcome | Adjusted estimates |
Ageno et al[28], 2021 | Mortality | Age, gender, and heparin use after admission, history of acute MI, T2D, HTN, cancer, COPD, renal function and CRP at hospital entry |
Arachchillage et al[29], 2022 | 90-day mortality, thrombosis, and ICU admission | Age, gender, BMI, antiplatelet treatment prior to admission, autoimmune disease, malignancy, hypercholesterolaemia, heart disease, T2D, smoking status, liver disease, lung disease, existing renal failure and whether renal failure was dialysis dependent |
Aslan et al[55], 2021 | In-hospital mortality | Age, male gender, T2D, ferritin, d-dimer, neutrophil, lymphocyte, creatinine, CRP, SaO2, procalcitonin, DOAC, HTN, HF, AF, CAD, COPD, systolic blood pressure and hematocrit in univariable logistic regression analysis |
Buenen et al[40], 2021 | All-cause mortality within 30 d | Age, sex, symptom duration, home medication, and comorbidities |
Covino et al[42], 2021 | All-cause in-hospital death. | Age, sex, comorbidity (categorized as CCI < 3 or CCI ≥ 3), and illness severity at admission (categorized as NEWS < 6 or NEWS ≥ 6) |
Gülcü et al[32], 2022 | In-hospital all-cause mortality | Age, gender, HTN, DM, HF, CAD, eGFR, albumin, CRP, D-dimer, hemoglobin, platelet count, LDH, and oxygen saturation variables |
Bauer et al[71], 2020 | Severity | Age and gender |
Ménager et al[60], 2020 | 7-day mortality | Age, sex, severe undernutrition, T2D, HTN, prior MI, HF, prior stroke and/or TIA, CHA2DS2-VASc score, HAS-BLED score, and eGFR |
Philipose et al[66], 2020 | Mortality | Age and gender |
Rieder et al[37], 2022 | COVID-19 related mortality | Age, gender, BMI and smoking status, the phase of disease at diagnosis, solid tumor, AF, CAD, prior MI, peripheral artery disease, HTN, cerebrovascular disease, and T2D |
Rivera-Caravaca et al[38], 2021 | Mortality and the composite of any thrombotic or thromboembolic event | Age, gender and ethnicity, all the included comorbidities |
Rodríguez-Molinero et al[67], 2020 | Mortality | Age, sex, obesity, and corticosteroids |
Russo et al[48], 2022 | Mortality | Age, arterial HTN, T2D, CAD, HF, previous stroke |
Schiavone et al[74], 2021 | Mortality | Age > 65 years, male gender, CAD, CKD, COPD, HF, OAC, PaO2/FiO2, hydroxychloroquine, tocilizumab, antivirals, heparin |
Spiegelenberg et al[50], 2021 | All-cause in hospital mortality and ICU admission | Age, sex, body mass index, active malignancy, COPD, T2D, HTN, CAD, MI, HF, non-ischaemic cardiomyopathy, previous heart surgery, electronic heart device, cerebrovascular accident, peripheral artery disease, immunosuppressive medication, no ICU policy |
Togano et al[39], 2021 | Severity (mechanical ventilation/ supplemental oxygen/SpO2 ≤ 94% on room air/tachypnea) | Age, gender, BMI, smoking, alcohol consumption, myocardial infarction/congestive heart failure, peripheral artery disease, cerebrovascular disease, dementia, paralysis, COPD, liver dysfunction, hypertension, hyperlipidemia, diabetes, obesity, leukemia, lymphoma, immunosuppression |
Tremblay et al[70], 2020 | All-cause mortality, mechanical ventilation | Age, gender, race, CCI and obesity |
van Haaps et al[51], 2021 | 21-day all-cause mortality and ICU admission | Age, gender, T2D, HTN, CKD, asthma, obesity, time in pandemic, center, chronic cardiac disease, malignancy, liver disease, dementia, organ transplant, autoimmune disorder, and rheumatic disorder |
Wargny et al[65], 2021 | Death within 28 d | Age |
Harrison et al[34], 2021 | 21-day all-cause in hospital mortality | Age, gender, and confounding variables |
Iaccarino et al[72], 2021 | Mortality, ICU admission | Age, multimorbidity (combined in the CCI score), and gender |
Hozayen et al[35], 2021 | Mortality | Age, sex, self-identified race/ethnicity (as a proxy for social, not biological risk factors), Elixhauser comorbidity score, and the presence/absence of any cardiovascular, immunological or hematological comorbidities |
Ho et al[45], 2021 | ICU admission, VTE, and mortality between date of SARS-CoV-2 diagnosis and 45 d after diagnosis | Age, sex, race/ethnicity, body mass index, CCI, HTN, T2D, and smoking history as well as the week of SARS-CoV-2 diagnosis |
Denas et al[43], 2021 | ICU admission and all-cause mortality | Age, sex, HF, HTN, cancer, T2D, history of stroke/TIA, previous bleeding, history of MI, peripheral artery disease, abnormal renal function, abnormal hepatic function, use of antiplatelet drugs, NSAIDs and statin use |
Corrochano et al[30], 2022 | All-cause mortality and ICU admission | Sex, age, CCI, and antithrombotic therapy |
Chocron et al[41], 2021 | In-hospital mortality and ICU admission | Sex, age, cardiovascular comorbidities (history of HTN, dyslipidemia, BMI, T2D, and current smoking), plasma creatinine level (µmol/L), CRP (mg/L), fraction of inspired oxygen, the degree of pulmonary lesions with ground-glass opacities and areas of consolidation, and the use of in-hospital anticoagulation (preventive low or high dose and therapeutic dose) |
- Citation: Iqbal K, Banga A, Arif TB, Rathore SS, Bhurwal A, Naqvi SKB, Mehdi M, Kumar P, Salklan MM, Iqbal A, Ahmed J, Sharma N, Lal A, Kashyap R, Bansal V, Domecq JP. Anticoagulant use before COVID-19 diagnosis prevent COVID-19 associated acute venous thromboembolism or not: A systematic review and meta-analysis. World J Methodol 2024; 14(3): 92983
- URL: https://www.wjgnet.com/2222-0682/full/v14/i3/92983.htm
- DOI: https://dx.doi.org/10.5662/wjm.v14.i3.92983